Cancer survival rates in the United States have reached unprecedented levels, reflecting decades of progress in prevention, early detection, and treatment. In 2025, it is estimated that over 2 million new cancer cases will be diagnosed, with approximately 618,000 deaths expected, underscoring the ongoing burden of this disease1 . Despite this, the cancer mortality rate has declined by 34% since 1991, resulting in nearly 4.5 million fewer deaths than would have occurred if rates had remained at their peak1 . This improvement is largely due to advances in screening, reductions in smoking, and innovative therapies that have transformed patient outcomes1 2.
Many Reasons Cancer Death Rates Are Declining in the U.S.
The steady decline in cancer death rates in the U.S. over the past three decades is a result of multiple factors working together. A major contributor has been the reduction in smoking rates, which has significantly lowered lung cancer incidence and mortality1 . Additionally, earlier detection through screening programs has increased the proportion of cancers diagnosed at localized stages, when treatment is more effective. Stomach, colorectal, and breast cancers have shown the greatest improvements in early detection due to widespread screening efforts3 .
Advances in treatment modalities, including surgery, radiation therapy, and immunotherapies, have also played a critical role in improving survival outcomes1 . Breakthroughs in therapies for melanoma and lung cancer, for example, have contributed to the overall decline in cancer mortality1 . Lung, colorectal, breast, and prostate cancers remain among the most common cancers in the U.S., and progress in these areas has driven much of the mortality reduction1 .
However, disparities persist. Native American and Black populations experience higher mortality rates for certain cancers, highlighting the need for equitable access to prevention, screening, and treatment services1 . The cancer burden also varies by state, with lung cancer incidence differing by more than threefold among men in different regions, reflecting variations in smoking prevalence and other risk factors1 .
- Reduction in tobacco use, especially cigarette smoking1
- Increased early detection through screening programs for breast, colorectal, and stomach cancers3
- Advances in surgical techniques and radiation therapy1
- Development and implementation of novel therapies, including immunotherapies1
- Improved management of common cancers such as lung, colorectal, breast, and prostate1
Immunotherapies: What Are They and How Do They Work?
Immunotherapy represents a revolutionary approach in cancer treatment by harnessing the patient's own immune system to recognize and attack cancer cells. Among the most impactful immunotherapies are immune checkpoint inhibitors (ICIs), which block proteins that cancer cells use to evade immune detection. Drugs such as pembrolizumab and nivolumab have demonstrated significant efficacy in treating advanced solid tumors4 .
These therapies are approved for more than 20 cancer types and can be administered through various routes, including intravenous, oral, or topical methods. They are often used alone or in combination with other treatments like chemotherapy or targeted therapies to enhance effectiveness4 . Some studies suggest that low-dose regimens of ICIs may provide similar survival benefits to standard doses, potentially reducing treatment costs and side effects, although the quality of evidence varies4 .
Immunotherapies have notably improved outcomes in cancers that were historically difficult to treat, such as melanoma and non-small cell lung cancer (NSCLC) 4. By reactivating the immune system, these therapies can lead to durable responses and prolonged survival in patients with advanced disease.
- Activation of the patient’s immune system to target cancer cells4
- Effectiveness across a wide range of solid tumors4
- Multiple administration routes (intravenous, oral, topical) 4
- Potential for combination with other treatment modalities4
- Emerging evidence supporting low-dose regimens to improve accessibility4
Related Stories
Which Cancers Have the Highest Survival Rates and Lowest Survival Rates?
Cancer survival rates vary widely depending on the type of cancer, stage at diagnosis, and available treatments. In high-income countries like Korea, the 5-year relative survival rate for breast cancer reached 72.9% between 2018 and 2022, reflecting advances in early detection and treatment3 . In contrast, in low-resource settings such as Ethiopia, the pooled 5-year survival rate for breast cancer is only 22.0%, largely due to late-stage diagnosis and limited access to care6 .
Cancers with effective screening programs and targeted treatments tend to have higher survival rates. For example, melanoma and lung cancer survival rates have improved substantially with the advent of targeted therapies and immunotherapies4 . Conversely, cancers without effective early detection or treatment options, such as pancreatic cancer, continue to have poor survival outcomes3 4.
| Cancer Type | 5-Year Relative Survival Rate | Notes |
|---|---|---|
| Breast (localized) | Up to 93% | Survival varies by race; Black women have lower survival partly due to later diagnosis2 |
| Prostate (localized) | Nearly 100% | Drops to 37% for distant-stage disease2 |
| Melanoma (overall) | 94% | >99% for localized stage; 35% for distant-stage disease2 |
| Lung and Bronchus | ~30% overall | Improved with immunotherapy and targeted therapies4 2 |
| Pancreatic | 13% overall | 44% for localized; very low due to late diagnosis and limited treatments2 |
| Ovarian | 51% overall | 92% for localized disease; high mortality due to late diagnosis2 |
Survival also differs by race and ethnicity, with Black populations generally experiencing lower survival rates across many cancer types, including breast, prostate, and cervical cancers1 2. These disparities underscore the importance of equitable access to early detection and high-quality treatment.
What Is the Key to Cutting Cancer Death Rates Even More?
Further reducing cancer mortality requires a multifaceted approach focused on early detection, equitable access to care, and continued research investment. The proportion of cancers diagnosed at localized stages has increased over time, particularly for stomach, colorectal, and breast cancers, largely due to effective screening programs3 . Early diagnosis improves treatment success and survival outcomes.
Despite progress, significant disparities remain. Native American and Black populations face higher mortality rates for several cancers, driven by factors such as socioeconomic status, access to screening, and treatment disparities1 . Addressing these inequities is critical to advancing cancer control for all populations.
Emerging technologies like artificial intelligence (AI) and machine learning show promise in improving cancer detection and risk stratification, although their clinical use is still developing7 . Lifestyle factors such as diet and exercise may influence cancer risk and outcomes, but evidence for their impact on survival is mixed1 .
Sustained investment in cancer research is essential to develop new treatments and improve existing ones. In 2025, over $450 million in grants are being funded by the American Cancer Society to support scientists working toward these goals1 8.
- Expand and improve access to cancer screening programs for early detection3
- Address racial, ethnic, and socioeconomic disparities in cancer care and outcomes1
- Invest in research for new treatments and technologies, including AI for detection1 7
- Promote lifestyle modifications that may reduce cancer risk1
- Enhance coordination of comprehensive cancer care and survivorship support1
